Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05876299 · ClinicalTrials.gov registry record · NA
The Anabolic Properties of a Lipid-rich Pork Matrix
A NA study, sponsored by University of Illinois at Urbana-Champaign.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT05876299: Completed NA study, sponsored by University of Illinois at Urbana-Champaign.
NCT05876299 is a NA study that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05876299, a NA study, has completed, sponsored by University of Illinois at Urbana-Champaign.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The amount and quality of skeletal muscle mass determines physical performance, but also a significant contributor to metabolic health. As such, the maintenance of skeletal muscle mass is relevant across the lifespan to remain active in family and community life. Food ingestion, particularly protein, is one of the main anabolic to skeletal muscle tissue by stimulating muscle protein synthesis rates. There have been multiple attempts to identify specialized performance nutrition products (e.g., various isolated protein powders) to maximize the anabolic properties of dietary protein on muscle. Our research group, however, has advocated for a food focus approach to meet dietary protein requirements. Particularly, we propose that whole foods demonstrate food matrix effects (nutrient-nutrient interactions) that creates a greater anabolic action on muscle beyond what amino acids can create alone. Therefore, the objective of this study is to identify the anabolic properties of consuming lipid-rich pork products when compared to their leaner counter-parts. Our working hypothesis that the ingestion of 84% or 96% lean ground pork condition will stimulate a greater increase in muscle protein synthesis rates compared to an isocaloric carbohydrate beverage in healthy adults. We further hypothesize that the ingestion of 84% lean pork will augment the stimulation of muscle protein synthesis rates to a greater extent than 96% lean ground pork. To achieve our objective, we will recruit 15 healthy men and women (20-50 y) to receive prime-constant infusions to directly measure muscle protein synthesis rates before and after treatment ingestion using our lab's established methods.
Primary Outcome
Rate of building new protein in skeletal muscle contractile protein
Interventions
- OTHER 95.1% Lean Pork
- OTHER 81.16% Lean Pork
- OTHER Carbohydrate Beverage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-07-15 |
| Est. Completion | 2024-04-09 |
| Phase | NA |
What the finished NCT05876299 record still lists
NCT05876299 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which 95.1% Lean Pork is the first listed.
NCT05876299 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05876299 about?
NCT05876299 is a clinical study titled "The Anabolic Properties of a Lipid-rich Pork Matrix". The amount and quality of skeletal muscle mass determines physical performance, but also a significant contributor to metabolic health. As such, the maintenance of skeletal muscle mass is relevant across the lifespan to remain active in family and community life. Food ingestion, particularly protein...
What is the current status of trial NCT05876299?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2023-07-15. Estimated completion is 2024-04-09.
What interventions are being tested in trial NCT05876299?
The interventions under investigation include: 95.1% Lean Pork (OTHER), 81.16% Lean Pork (OTHER), Carbohydrate Beverage (OTHER).
Who is sponsoring clinical trial NCT05876299?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05876299's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI